RLAY Q1 2022 Earnings — Relay Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RLAYRelay Therapeutics, Inc.

$2B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$419,000-56.0% YoY

Gross Profit

-$51M-12231.0% margin

Operating Income

-$63M-14969.2% margin

Net Income

-$62M-14808.1% margin

EPS (Diluted)

$-0.48

QoQ Revenue Growth

-26.1%

Cash Flow

Operating Cash Flow

-$49M

Free Cash Flow

-$52M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$950M

Total Liabilities

$108M

Stockholders' Equity

$842M

Cash & Equivalents

$119M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$419,000	$952,000	-56.0%
Gross Profit	-$51M	-$30M	-72.7%
Operating Income	-$63M	-$42M	-47.9%
Net Income	-$62M	-$42M	-47.1%

Revenue Segments

License

$200,000100%